Treace Medical Concepts Free Cash Flow (FCF) History (TMCI)
Treace Medical Concepts reported −$29.5M in free cash flow for fiscal 2025, an increase of $19.3M from the previous fiscal year, with a free cash flow margin of −13.86%.
View full Treace Medical Concepts company overviewTreace Medical Concepts free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | −$29.5M | $19.3M | — | −13.86% |
| 2024 | 2024-12-31 | −$48.8M | −$2.7M | — | −23.29% |
| 2023 | 2023-12-31 | −$46.0M | −$547,000 | — | −24.60% |
| 2022 | 2022-12-31 | −$45.5M | −$25.6M | — | −32.07% |
| 2021 | 2021-12-31 | −$19.9M | −$14.3M | — | −21.07% |
| 2020 | 2020-12-31 | −$5.6M | $3.3M | — | −9.70% |
| 2019 | 2019-12-31 | −$8.9M | — | — | −22.54% |
Treace Medical Concepts quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | −$6.9M | $918,000 | — | −15.20% |
| Q1 2026 | 2026-03-31 | $4.2M | $3.5M | +537.86% | +8.85% |
| Q4 2025 | 2025-12-31 | −$10.4M | −$3.1M | — | −16.67% |
| Q3 2025 | 2025-09-30 | −$11.9M | $2.8M | — | −23.70% |
| Q2 2025 | 2025-06-30 | −$7.8M | $7.8M | — | −16.50% |
| Q1 2025 | 2025-03-31 | $655,000 | $11.8M | — | +1.25% |
| Q4 2024 | 2024-12-31 | −$7.3M | −$5.6M | — | −10.60% |
| Q3 2024 | 2024-09-30 | −$14.7M | −$1.7M | — | −32.62% |
| Q2 2024 | 2024-06-30 | −$15.6M | −$3.1M | — | −35.15% |
| Q1 2024 | 2024-03-31 | −$11.1M | $7.6M | — | −21.81% |
| Q4 2023 | 2023-12-31 | −$1.7M | $6.0M | — | −2.76% |
| Q3 2023 | 2023-09-30 | −$13.0M | $326,000 | — | −31.93% |
| Q2 2023 | 2023-06-30 | −$12.6M | $3.2M | — | −29.95% |
| Q1 2023 | 2023-03-31 | −$18.7M | −$10.0M | — | −44.41% |
| Q4 2022 | 2022-12-31 | −$7.7M | −$3.0M | — | −15.45% |
| Q3 2022 | 2022-09-30 | −$13.3M | −$3.1M | — | −40.36% |
| Q2 2022 | 2022-06-30 | −$15.7M | −$11.3M | — | −52.50% |
| Q1 2022 | 2022-03-31 | −$8.7M | −$8.1M | — | −30.03% |
| Q4 2021 | 2021-12-31 | −$4.7M | −$7.0M | — | −13.91% |
| Q3 2021 | 2021-09-30 | −$10.2M | −$5.9M | — | −47.19% |
| Q2 2021 | 2021-06-30 | −$4.4M | −$2.3M | — | −21.31% |
| Q1 2021 | 2021-03-31 | −$642,000 | $927,000 | — | −3.43% |
| Q4 2020 | 2020-12-31 | $2.4M | — | — | +9.79% |
| Q3 2020 | 2020-09-30 | −$4.3M | — | — | −29.86% |
| Q2 2020 | 2020-06-30 | −$2.1M | — | — | −27.06% |
| Q1 2020 | 2020-03-31 | −$1.6M | — | — | −13.94% |
Treace Medical Concepts free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from −$5.6M to −$29.5M, a net decrease of $23.9M. Treace Medical Concepts's latest reported quarter, Q2 2026, generated −$6.9M in free cash flow, an increase of $918,000 year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Treace Medical Concepts filings at SEC.gov ↗